SpyGlass Pharma Reports Progress on Bimatoprost Drug Delivery Systems

SpyGlass Pharma, a late-stage biopharmaceutical company, reported significant progress in its third quarter 2026 financial results and provided corporate updates on its pipeline. The company, founded in 2019 by Malik Y. Kahook, M.D., and Glenn Sussman, has made strides in advancing its drug delivery technology for treating glaucoma and ocular hypertension.

In October, SpyGlass Pharma completed the acquisition of Advanced Vision Science, Inc. (AVS), a wholly owned subsidiary of Santen Pharmaceutical Co., Ltd., for approximately $13 million in cash. This acquisition secured scalable commercial intraocular lens (IOL) manufacturing capacity for the Bimatoprost Drug Pad-IOL System (BIM-IOL System) and accelerated the expansion of its premium IOL portfolio.

The BIM-IOL System, designed to be implanted during routine cataract surgery, demonstrated groundbreaking four-year first-in-human (FIH) efficacy and safety follow-up data. The data showed a 37% reduction in mean intraocular pressure (IOP) across all dose levels, with 86% of patients remaining off all topical IOP-lowering drops. Additionally, 90% of patients maintained a best corrected distance visual acuity (BCDVA) of 20/25 or better. SpyGlass Pharma plans to work with the U.S. Food and Drug Administration (FDA) to advance the program through a 505(b)(2) New Drug Application (NDA) submission.

Enrollment in the registrational Phase 3 trials of the BIM-IOL System remains on track, with completion expected in 2027. SpyGlass Pharma also announced the successful completion of first implantations in the FIH study of the Bimatoprost-Drug Ring System (BIM-DRS), a non-IOL-based sustained drug delivery system for glaucoma. The BIM-DRS is designed to deliver bimatoprost for up to seven years, offering continuous care over the lifetime of a patient.

Financially, SpyGlass Pharma reported cash, cash equivalents, and short-term investments of $215.8 million as of September 30, 2026, which are expected to fund planned operations through 2028. Research and development expenses for the third quarter of 2026 were $10.0 million, up from $8.1 million in the same period of 2025, primarily due to the hiring of clinical personnel and continued enrollment in the Phase 3 registrational trials for the BIM-IOL System. General and administrative expenses were $16.2 million for the third quarter of 2026, compared to $3.0 million in the same period of 2025, mainly due to higher professional service fees and personnel costs.

The net loss for the third quarter of 2026 was $24.3 million, or ($0.73) per basic and diluted share, compared to $9.8 million, or ($4.53) per basic and diluted share, in the same period of 2025. Despite the financial challenges, SpyGlass Pharma remains committed to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery solutions.

In October, Jeffrey Kammer, M.D., associate professor of ophthalmology at Vanderbilt University, presented topline 12-month Phase 1/2 data at the American Academy of Ophthalmology (AAO) Annual Meeting. The data reinforced the sustained IOP reduction and the elimination of topical eye drops for 98% of patients who received the intended commercial dose of the BIM-IOL System. The BIM-IOL System, comprising novel, proprietary non-bioerodible drug pads attached to its intraocular lens, was designed to be implanted during routine cataract surgery to reduce elevated IOP in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).